Ecstacy may be used to treat post-trauma stress

16 March 2009

The "street drug" Ecstasy may help suffers of post-traumatic stress learn to deal with their memories, according to an article in the  Journal of Psychopharmacology.

Studies have shown that a type of psychological treatment called  exposure therapy - where the patient repeatedly recalls the traumatic  experience or is repeatedly exposed to situations that are safe, but  still trigger their traumatic feelings - can be effective in relieving  stress responses in patients with post-traumatic stress disorder and  other anxious conditions. To improve outcomes, scientists have been  investigating the use of drug therapies to enhance the effect of  exposure therapy, making the result of exposure to the fear trigger  easier, faster and more effective.

Psychiatrists that have administered  3,4-methylenedioxy-N-methylamphetamine, most commonly known by the  street name ecstasy, to anxiety patients have noted that it promotes  emotional engagement; strengthens the bond between the patient and  doctor, known as the therapeutic alliance; decreases emotional  avoidance; and improves tolerance for recall and processing of painful  memories.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight